Rockwell Medical, Inc. (Nasdaq: RMTI) announced its financial results for the fourth quarter and full-year ended December 31, 2025, revealing a notable increase in net sales and profitability. For the fourth quarter, the company reported net sales of $18.3 million, a decrease from $24.7 million in the same period of 2024, while full-year net sales reached $69.3 million, down from $101.5 million in 2024. Despite the decline in sales, Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the second consecutive year, with an Adjusted EBITDA of $1.0 million for Q4 2025, compared to $1.3 million in Q4 2024. The company also reported a gross margin of 21% for Q4 2025, a significant improvement from 15% in the same quarter of the previous year.

The company’s cash flow from operating activities was positive, generating $2.3 million in Q4 2025, which increased its cash position to $25.0 million at year-end. Rockwell Medical's CEO, Mark Strobeck, emphasized the company's focus on aligning its infrastructure with demand and maintaining profitability amidst changes in customer base and purchase volumes. The company also extended its product purchase agreement with a major dialysis provider through December 2026, which includes increased product pricing.

Looking ahead, Rockwell Medical aims to drive sustainable growth by adding new customers, renewing contracts, and enhancing operational efficiencies. The company has set its 2026 annual guidance, projecting Adjusted EBITDA between $1 million to $2 million and positive operating cash flow. Rockwell Medical remains committed to delivering high-quality hemodialysis products and services, positioning itself for long-term stability and success in the healthcare market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.